Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study (Q47321369)

14 January 2018

title

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study (English)

1 reference

14 January 2018

main subject

type 2 diabetes

0 references

lorcaserin hydrochloride

1 reference

lorcaserin hydrochloride hemihydrate

ChEBI release 2020-05-28

ChEBI ID

65350

1 reference

ChEBI release 2020-05-28

1 reference

Patrick M O'Neil

1

1 reference

14 January 2018

Steven R Smith

2

1 reference

14 January 2018

Neil J Weissman

3

1 reference

14 January 2018

Meredith C Fidler

4

1 reference

14 January 2018

Matilde Sanchez

5

1 reference

14 January 2018

Jinkun Zhang

6

1 reference

14 January 2018

Brian Raether

7

1 reference

14 January 2018

Christen M Anderson

8

1 reference

14 January 2018

William R Shanahan

9

1 reference

14 January 2018

publication date

16 March 2012

1 reference

14 January 2018

published in

Obesity

1 reference

14 January 2018

volume

20

1 reference

14 January 2018

issue

7

1 reference

14 January 2018

page(s)

1426-1436

1 reference

14 January 2018

Serotonergic drugs : effects on appetite expression and use for the treatment of obesity

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Multicenter, placebo-controlled trial of lorcaserin for weight management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Managing type 2 diabetes: balancing HbA1c and body weight

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Weight loss in type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Treating diabetes and prediabetes by focusing on obesity management.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

The assessment of binge eating severity among obese persons.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and doppler echocardiography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Use of multiple views in the echocardiographic assessment of pulmonary artery systolic pressure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Standards of medical care in diabetes--2011.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Lipoprotein responses to weight loss and weight maintenance in high-risk obese subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Overweight, obesity, and blood pressure: the effects of modest weight reduction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Development of a brief measure to assess quality of life in obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

MTNR1B G24E variant associates With BMI and fasting plasma glucose in the general population in studies of 22,142 Europeans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2012.66

31 March 2020

Identifiers

DOI

10.1038/OBY.2012.66

1 reference

14 January 2018

1 reference

14 January 2018